Related Experiment Video
Updated: Jul 18, 2026
12:28
Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies
Published on: March 12, 2022
Molecular targets for retinal vascular diseases.
1Departments of Ophthalmology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-9277, USA. pcampo@jhmi.edu
Journal of Cellular Physiology
|November 30, 2006
Summary
Identifying validated molecular targets, like vascular endothelial growth factor (VEGF), drives new treatments for retinal vascular diseases. Research continues to find and validate additional therapeutic targets.
Area of Science:
- Ophthalmology
- Molecular Biology
- Pharmacology
Background:
- Disease molecular pathogenesis elucidated in animal models offers potential therapeutic targets.
- Validated targets, confirmed through clinical trials showing patient benefit, stimulate further research.
- Vascular Endothelial Growth Factor (VEGF) is a validated target for several retinal vascular diseases.
Purpose of the Study:
- To review preclinical and clinical trial outcomes of VEGF antagonists.
- To present evidence for other molecules as potential therapeutic targets in retinal diseases.
Main Methods:
- Literature review of preclinical studies on VEGF antagonists.
- Analysis of clinical trial data for VEGF antagonist efficacy and safety.
- Evaluation of emerging molecular targets based on current research.
Main Results:
- VEGF antagonists have led to beneficial treatments for patients with retinal vascular diseases.
- Significant research activity has intensified following VEGF target validation.
- Several other molecules are under investigation as potential therapeutic targets.
Conclusions:
- Validated molecular targets are crucial for developing effective treatments for complex diseases.
- VEGF antagonism represents a successful therapeutic strategy in retinal vascular diseases.
- Ongoing research is identifying and validating new molecular targets for future therapies.
More Related Videos
Related Concept Videos
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...